Literature DB >> 20107738

Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) and prothrombin G20210A heterozygosity: response to t-PA therapy.

Joana Antunes, Paulo Filipe, Marisa André, Ana Fraga, Gabriel Miltenyi, Manuel Marques Gomes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20107738     DOI： 10.2340/00015555-0760

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN： 0001-5555            Impact factor:   4.437


× No keyword cloud information.
  5 in total

1.  Livedoid vasculopathy in a patient with lupus anticoagulant and MTHFR mutation: treatment with low-molecular-weight heparin.

Authors:  Jihane Abou Rahal; Rim S Ishak; Zaher K Otrock; Abdul-Ghani Kibbi; Ali T Taher
Journal:  J Thromb Thrombolysis       Date:  2012-11       Impact factor: 2.300

2.  Plasminogen activator inhibitor-1: a potential etiological role in livedoid vasculopathy.

Authors:  Yimeng Gao; Hongzhong Jin
Journal:  Int Wound J       Date:  2020-10-11       Impact factor: 3.315

Review 3.  Livedoid vasculopathy: A multidisciplinary clinical approach to diagnosis and management.

Authors:  Asli Bilgic; Salih Ozcobanoglu; Burcin Cansu Bozca; Erkan Alpsoy
Journal:  Int J Womens Dermatol       Date:  2021-09-02

4.  Painless Livedoid Vasculopathy in a Patient with G20210A Prothrombin Gene Mutation.

Authors:  Aibek E Mirrakhimov; Erwin Velasquez Kho; Alaa Ali
Journal:  Case Rep Med       Date:  2012-09-05

Review 5.  From dermatological conditions to COVID-19: Reasoning for anticoagulation, suppression of inflammation, and hyperbaric oxygen therapy.

Authors:  Paulo Ricardo Criado; Hélio Amante Miot; Thais Prota Hussein Pincelli; Alexandre Todorovic Fabro
Journal:  Dermatol Ther       Date:  2020-11-30       Impact factor: 3.858
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.